{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T20:50:09Z","timestamp":1760820609681,"version":"3.40.5"},"reference-count":18,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,8,1]],"date-time":"2014-08-01T00:00:00Z","timestamp":1406851200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1016\/j.trim.2014.06.001","type":"journal-article","created":{"date-parts":[[2014,6,13]],"date-time":"2014-06-13T06:47:41Z","timestamp":1402642061000},"page":"92-97","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"title":["Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil"],"prefix":"10.1016","volume":"31","author":[{"given":"Kazuya","family":"Kabei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0113-8058","authenticated-orcid":false,"given":"Junji","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoaki","family":"Iwai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Yamasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Kuwabara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihide","family":"Naganuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norihiko","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.trim.2014.06.001_bb0005","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/j.1600-6143.2004.00653.x","article-title":"ABO incompatible kidney transplantations without splenectomy, using antigen-specific immunoadsorption and rituximab","volume":"5","author":"Tyd\u00e9n","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2014.06.001_bb0010","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/j.1399-3089.2006.00277.x","article-title":"Pinpoint targeted immunosuppression: anti-CD20\/MMF desensitization with anti-CD25 in successful ABO-incompatible kidney transplantation without splenectomy","volume":"13","author":"Saito","year":"2006","journal-title":"Xenotransplantation"},{"key":"10.1016\/j.trim.2014.06.001_bb0015","doi-asserted-by":"crossref","first-page":"3900","DOI":"10.1182\/blood.V95.12.3900","article-title":"Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis","volume":"95","author":"Golay","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.trim.2014.06.001_bb0020","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1097\/01.tp.0000261113.30757.d1","article-title":"Rituximab therapy for acute humoral rejection after kidney transplantation","volume":"83","author":"Faguer","year":"2007","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2014.06.001_bb0025","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/j.1399-0012.2004.00292.x","article-title":"Refractory acute kidney transplant rejection with CD20 graft infiltrates and successful therapy with rituximab","volume":"19","author":"Alausa","year":"2005","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trim.2014.06.001_bb0030","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.3109\/10428194.2012.679266","article-title":"Late-onset neutropenia following primary treatment of diffuse large B-cell lymphoma with rituximab-containing therapy","volume":"53","author":"Rozman","year":"2012","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.trim.2014.06.001_bb0045","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/MOH.0b013e32834da987","article-title":"Neutropenia after rituximab treatment: new insights on a late complication","volume":"19","author":"Wolach","year":"2012","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.trim.2014.06.001_bb0055","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1056\/NEJMc0808481","article-title":"B-cell-depleting induction therapy and acute cellular rejection","volume":"360","author":"Clatworthy","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.trim.2014.06.001_bb0060","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.trim.2013.01.003","article-title":"Late-onset neutropenia (LON) after low-dose rituximab treatment in living related kidney transplantation-single-center study","volume":"28","author":"Ishida","year":"2013","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.trim.2014.06.001_bb0070","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.transproceed.2011.11.006","article-title":"Excellent outcomes of ABO-incompatible kidney transplantation: a single-center experience","volume":"44","author":"Uchida","year":"2012","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2014.06.001_bb0075","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000324103","article-title":"Clinical outcome of ABO-incompatible living unrelated donor kidney transplantation","volume":"86","author":"Uchida","year":"2011","journal-title":"Urol Int"},{"key":"10.1016\/j.trim.2014.06.001_bb0080","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1007\/s11255-012-0231-z","article-title":"ABO-incompatible kidney transplantation in elderly patients over 60years of age","volume":"44","author":"Uchida","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"10.1016\/j.trim.2014.06.001_bb0085","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1016\/j.transproceed.2008.06.018","article-title":"A novel approach to successful ABO-incompatible high-titer renal transplantation","volume":"40","author":"Uchida","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2014.06.001_bb0090","doi-asserted-by":"crossref","first-page":"3998","DOI":"10.1016\/j.transproceed.2010.09.043","article-title":"Desensitization protocol in highly HLA-sensitized and ABO-incompatible high titer kidney transplantation","volume":"42","author":"Uchida","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.trim.2014.06.001_bb0095","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/j.1399-0012.2010.01384.x","article-title":"The low dose of rituximab in ABO-incompatible kidney transplantation without a splenectomy: a single-center experience","volume":"25","author":"Shirakawa","year":"2011","journal-title":"Clin Transplant"},{"key":"10.1016\/j.trim.2014.06.001_bb0100","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1097\/01.tp.0000184275.81396.45","article-title":"Delayed-onset neutropenia in a patient receiving rituximab as treatment for refractory kidney transplantation","volume":"80","author":"Mitsuhata","year":"2005","journal-title":"Transplantation"},{"key":"10.1016\/j.trim.2014.06.001_bb0105","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/j.1600-6143.2005.01088.x","article-title":"Is administration of rituximab at 375mg\/m without splenectomy appropriate for ABO-incompatible renal transplant?","volume":"5","author":"Mitsuhata","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1016\/j.trim.2014.06.001_bb0110","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ctr.12281","article-title":"Conversion of stable ABO-incompatible kidney transplant recipients from mycophenolate mofetil with standard exposure calcineurin inhibitors (CNIs) to everolimus with very low exposure CNIs\u2014a short-term pilot study","volume":"28","author":"Uchida","year":"2014","journal-title":"Clin Transplant"}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327414000446?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327414000446?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T23:35:23Z","timestamp":1597966523000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327414000446"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8]]},"references-count":18,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0966327414000446"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2014.06.001","relation":{},"ISSN":["0966-3274"],"issn-type":[{"type":"print","value":"0966-3274"}],"subject":[],"published":{"date-parts":[[2014,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Late-onset neutropenia and acute rejection in ABO-incompatible kidney transplant recipients receiving rituximab and mycophenolate mofetil","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2014.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}